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review and meta-analysis of observational
studies
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Abstract
Background: The effectiveness of antiretroviral therapy (ART) depends on the choice of regimens during initiation.
Most evidences from developed countries indicated that there is difference between efavirenz (EFV) and nevirapine
(NVP). However, the evidences are limited in resource poor countries particularly in Africa. Thus, this systematic review
and meta-analysis was carried out to summarize reported long-term treatment outcomes among people on first line
therapy in sub-Saharan Africa.
Methods: Observational studies that reported odds ratio, relative risk, hazard ratio, or standardized incidence ratio to
compare risk of treatment failure among HIV/AIDS patients who initiated ART with EFV versus NVP were systematically
searched. Searches were conducted using the MEDLINE database within PubMed, Google Scholar, HINARI, and
Research Gates between 2007 and 2016. Information was extracted using standardized form. Pooled risk ratios (RR) and
95% confidence intervals (CI) were calculated using random-effect, generic inverse variance method.
Result: A total of 6394 articles were identified, of which, 29 were eligible for review and abstraction in sub-Saharan Africa.
Seventeen articles were used for the meta-analysis. Of a total of 121,092 independent study participants, 76,719 (63.36%)
were females. Of these, 40,480 (33.43%) initiated with NVP containing regimen. Two studies did not report the median
CD4 cell counts at initiation. Patients who have low CD4 cell counts initiated with EFV containing regimen. The pooled
effect size indicated that treatment failure was reduced by 15%, 0.85 (95%CI: 0.75–0.98), and non-nucleoside reverse
transcriptase inhibitor (NNRTI) switch was reduced by 43%, 0.57 (95%CI: 0.37–0.89).
Conclusion: The risk of treatment failure and NNRTI switch were lower in patients who initiated with EFV than NVP-
containing regimen. The review suggests that initiation of patients with EFV-containing regimen will reduce treatment
failure and NNRTI switch.
Keywords: Treatment failure, NNRTI switch, First line ART regimen, Systematic review, Sub-Saharan Africa
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Background
During the last three decades, HIV/AIDS has become the
threat to the world. Almost 75 million people have been
infected, and about 36 million people have died of HIV
[1]. The introduction of antiretroviral therapy (ART)
changes HIV/AIDS from diseases with a high mortality
rate to manageable chronic diseases by decreasing the
progression of AIDS and reducing HIV-related illness and
deaths. Researches revealed that improved access to ART
is helping to drive a decline in HIV-related morbidity and
mortality [2–5]. In the USA and Canada, a person in his
or her 20s who contracts HIV can now expect to live into
the 70s if initiated ART early [6].
The standard therapy consists of two nucleoside reverse
transcriptase inhibitors (NRTIs) and one non-nucleoside
reverse transcriptase inhibitor (NNRTI) [7]. In 2010, these
guidelines were revised and recommended less toxic drugs
in first-line therapy by replacing stavudine (d4T) with
tenofovir (TDF) [8]. In resource-limited countries, World
Health Organization (WHO) recommends the use of two
NNRTI (nevirapine (NVP) and efavirenz (EFV)) as first-
line ART regimen. EFV, combined with two NRTIs, is the
recommended option for initial therapy and is the most
widely used NNRTI [9].
Staying on an initial regimen medication that success-
fully suppresses viral replication is essential as it slows
disease progression and preserves options for future treat-
ment [3]. However, patients modify or switch their regi-
men due to different reasons. Toxicity is the most
frequently reported reason for modifying or switching the
first combined antiretroviral therapy regimens [10]. Once
a drug combination is modified, it can no longer be given
to the same patient again. It also causes significant
morbidity and poor quality of life and also can be an
important barrier to adherence, ultimately resulting in
treatment failure and viral resistance [11]. Treatment
failure due to different reasons is the challenge faced
by the current ART scale up program especially in
resource-limited countries [12, 13]. Where as the
resource-rich countries have documented the effect-
iveness of the choice of initial regimen [14].
In resource-limited countries, the available evidences
are not consistent with the effectiveness of NNRTI
choice. In Cameroon, hematologic related adverse drug
reaction was high among those who started ART which
leads to treatment modification [15]. According to a
Ghanaian study, the effectiveness of first-line ART (i.e.,
the proportion of patients who stay on the initial regi-
men) was 83.3% depending on virologic failure [16].
Documented virologic failure suggests that access to
viral load measurements may actually reduce the rate of
switching to a second-line regimen [17]. The substitu-
tion due to toxicity of NVP was higher, and according to
[18], 8 and 2% substitute their initial regimen when
initiated with NVP and EFV, respectively. Study in
southern Ethiopia [19] showed that most modifications
had occurred during the first 6 months of treatment.
Studies in resource-rich settings revealed that EFV-
containing regimen has better treatment outcomes than
NVP-containing regimen [20, 21]. In India, a randomized
clinical trial [22] also showed that regimen containing
NVP was inferior and was associated with more frequent
virologic failure and death. Similarly, this pattern was re-
ported in Swaziland, Zambia, and Botswana [23, 24].
However, studies in Ghana and Ethiopia indicated that
there is comparable effect between EFV and NVP [16, 25].
The choice of treatment combinations for HIV-
infected patients to initiate ART depends on cost and
efficacy [7, 26]. Identifying the long-term treatment out-
comes of these drugs is very decisive for clinical
decision. Clinical decision-making requires ongoing rec-
onciliation of studies that provide different answers to
the same question. The above example indicates contra-
dicting results in terms of the effectiveness of the drugs.
Though studies showed significantly different effect on
long-term treatment outcome in resource-rich settings
among NNRTI groups, there was no strong evidence in
resource-poor countries. Thus, local evidences as per
the real setting of the population will assist the clinicians
to focus on the most effective treatment combinations in
resource-poor settings. This review aimed to investigate
if treatment failure and NNRTI substitution are different
between NVP and EFV containing initial regimen.
Methods
Search strategies
Comprehensive and exhaustive search strategy was
made by two of the investigators to identify all
relevant studies. MEDLINE through PubMed, Google
Scholar, HINARI, and Research Gates were used to
search for the relevant papers. Population, Interven-
tion, Comparison and Outcome (PICO) format was
used to search the relevant studies. PROSPERO
registration was not done.
For HIV-infected adults a combination of NRTI and
NNRTI drugs has been given as first-line regimen. NVP
and EFV are used as first-line drugs for most of the pa-
tients. The research question was “Does the choice of
NNRTI drug affect the effectiveness of first line treat-
ment?” The search strategy included Medical Subject
Heading (MeSH) terms and a range of relevant keywords.
Combinations of keywords: (((((((((((((HIV) OR AIDS*)
AND antiretroviral*) OR HAART*) OR ART*) OR ARV*)
AND NNRTI*) AND outcomes*) OR treatment failure)
OR switch) OR substitution) OR Discontinuation) AND
Africa) OR sub-Saharan Africa. The authors were con-
tacted and requested full articles by email when the article
was not accessed from these sources.
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Inclusion criteria
The study eligibility was determined using the following
criteria:
Type of studies: Epidemiological study designs done in
sub-Saharan Africa, including cohort, case-control, and
retrospective follow-up, comparative cohort, and analyt-
ical cross-sectional studies, were included.
Intervention: This review include studies that evaluated
EFV compared to NVP-containing regimens in a com-
bination of three antiretroviral drugs. If cohorts report
on other drugs in combination with EFV or NVP, or two
NRTIs and a protease inhibitor, then only data for
combination ART of two NRTIs with NVP or EFV were
extracted.
Types of outcome measures: This review considered
studies that included treatment failure or NNRTI switch
as an outcome measure. Studies published between 2007
and 2016 in English language were included.
Exclusion criteria
Studies which were conducted among children (age <
15 years), published other than English language, and
initiated ART other than NNRTI drugs were excluded
from the review.
Study selection
The selection of studies from electronic databases was
conducted in two stages: First decision was made based
on titles and, where available, abstracts. Second, for
studies that met the inclusion criteria, or in cases when
a definite decision could not be made based on the title
and/or abstract alone, the full paper was obtained for
detailed assessment against the inclusion criteria. Two
independent reviewers assessed study quality. The Kappa
statistics was 0.86 which indicates the presence of good
agreement between the reviewers. The papers were given
to third reviewer for consensus while a discrepancy in
decision process.
Quality assessment tools
Quality assessment of the included studies was also in-
dependently performed using the Joanna Briggs Institute
Meta-Analysis of Statistics Assessment and Review In-
strument (JBI-MAStARI) [27] and Newcastle-Ottawa
quality assessment scale [28] by two independent
reviewers. The first assessment tool consisted of nine
questions. The later consisted of eight multiple-choice
questions that addressed subject selection and compar-
ability (of cases and controls in case-control studies, of
cohorts in cohort studies) and the assessment of the out-
come (in case-control studies) or exposure (in cohort
studies). The number of possible answers per question
ranged from two to five. High-quality responses earned
a star, totaling up to nine stars.
Data extraction process
A standardized data collection form [29] was used to
extract necessary data from the articles: the title of the
study, first author’s last name, country where the study
was conducted, study design, year of recruitment and
follow-up, year of publication, sample size, study popula-
tion, diagnosis and identification of treatment modifica-
tion, average duration of follow-up (for cohort study),
potential confounders that were adjusted for, main find-
ings and quality assessment tools. Any data discrepancy
was resolved by referring back to the original study.
Pretesting the data extraction tool
The selection process and data collection tool was pre-
tested based on the inclusion criteria on five articles. It
was aimed to check reliability of interpretation and
classification of the studies appropriately and to ensure
that all the relevant information was captured. The
consistency of extracted data was assessed to reduce
data extraction errors.
Outcome measures
Treatment failure was defined as either virologic, clin-
ical, or immunological failure as per the definition of
WHO ART guideline [8]. Studies which used composite
outcome as their event was also defined as treatment
failure. NNRTI substitution was defined as either
NNRTI modification, regimen change, NNRTI resist-
ance, or NNRTI discontinuation.
Data synthesis and statistical analysis
Heterogeneity among studies was examined using I-
squared statistic. According to the test, I-square estimate
greater than 50% was considered as indicative of moder-
ate to high levels of heterogeneity [30]. Adjusted point
estimates were extracted from individual studies and
combined together to calculate the pooled estimates.
The DerSimonian-Laird random effects method was
used to incorporate an additional between study compo-
nent to the estimate of variability [31, 32]. Subgroup
analyses were done to explore differences in outcomes
according to study outcomes. The qualitative and
quantitative methods were used to present the data
extracted from each study. Funnel plot and Egger’s test
were used to check the presence of publication bias [33].
We plotted the effects by the inverse of its standard
error. The symmetry of such plots was assessed both by
using visually and with Egger’s test to see if the effect de-
creased with increasing sample size. Since graphical
evaluation can be subjective, we conducted a regression
asymmetry test as formal statistical tests for the presence
of publication bias.
Meta-regression was conducted to investigate the im-
pact of study characteristics on the study estimates of
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relative risk. The natural logarithm of the risk ratio was
the dependent variable, and length of follow-up, median
baseline CD4 cell counts, median age, proportion of fe-
male and year of publication were entered as explanatory
variable. P value and 95% confidence interval were used
to test statistical significant. Statistical analysis was per-
formed using Stata version 12 software and Review
Manager Version 5.3. Stata does not have built-in meta-
analysis command; however, user written command
called metan is available. Steps to install the command
can be obtained from the book of Egger [34]. PRISMA
2009 checklist was used to keep the standard of the re-
port (see Additional file 1).
Results
For inclusion in this review, studies were required to
provide comparisons of NVP and EFV on the risk of
long-term outcomes. A total of 6394 articles were identi-
fied in English language and human domain restrictions,
of which, 5779 were rejected by looking only at the title
of the research. The remaining 615 articles were further
screened, and subsequently, 395 were considered irrele-
vant or duplicates. The abstracts of 238 articles were
then evaluated independently. Of these, 158 records
were excluded because of no comparison groups of the
outcomes of interest, missing comparison of EFV versus
NVP drugs and reviews and meta-analysis. The PRISMA
flow diagram [35] is used to present stages of review
process (Fig. 1).
A study done on comparison between NVP and
lopinavir-ritonavir [36] was excluded as it was not the
interest of this review. Other six papers were excluded
as the studies were conducted among children [37],
conducted outside of sub-Saharan Africa, [38, 39, 40, 41],
and systematic reviews and meta-analysis articles [20]
were. Subsequently, of 79 full record articles, a total of 36
were eligible studies. Further, the full text of 36 articles
were reviewed in detail, and 20 of them were excluded
due to lack of sufficient information on sample size,
design, and analysis. Study [42] used case-control design,
and the sample size was small for both the cases and con-
trols. It was not also clear how the size was determined.
Study [43] had used cross-sectional study design, and the
assessment tools might not evaluate the quality appropri-
ately. Therefore, 16 studies were included in the quantita-
tive synthesis out of which 17 outcome measures were
identified for meta-analysis.
Quality assessment
Two independent reviewers assessed the articles prior to
inclusion to maintain methodological validity using the
Joanna Briggs Institute Meta-Analysis of Statistics
Assessment and Review Instrument (JBI-MAStARI) [27].
The scores ranged from 5/9 to 8/9 in absolute number
Fig. 1 The PRISMA flow diagram of identification and selection of studies for the systematic review and meta-analysis
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and 55.6 to 88.9% in percentage. In addition, Newcastle-
Ottawa quality assessment scale was used. The scores
for each study ranged from 4 to 7 stars (from a total of
9).
Characteristics of included studies
All the 16 studies were conducted between 2007 and
2016. Sample size ranges from 167 [43] to 27,350 [44]
patients. A total of 70,537 patients were included in all
the studies. Of whom, 45,010 (63.8%) were females. The
proportion of females ranges from 51 to 72%. Most of
the patients, 42,039 (59.6%), were initiated with EFV-
containing regimen. Overall, more females were initiated
with NVP-containing regimens. The median follow-up
time was 4 years (IQR 3–7). Study [45] had the longest
follow-up time whereas studies [46, 47] had followed for
shorter periods.
Almost half of the studies were from South Africa
[43–49], the rest were from Kenya [50, 51], Ghana [10,
52], Nigeria [42], Zambia [50], Ethiopia [25, 53], and
sub-Saharan Africa [54, 55]. Study [50] was a multicen-
ter study (in Kenya, Zambia, and Thailand), and data
from Kenya and Zambia were taken due to inclusion cri-
teria. A total of 509 and 152 patients were included in
Zambia and Kenya, respectively. With regard to the
study design, most were retrospective cohort [9]. The
minimum and maximum median age for the included
studies were 32 (IQR 28–36) and 40 (IQR 35–47) years,
respectively. In almost all studies, high median age cor-
responds to EFV-containing regimen at initiation. The
median CD4 cell counts ranges from 67 (IQR 21–161)
to 192 (IQR 112–324). The median CD4 cell count was
smaller for patients who initiated with EFV-containing
regimen. This might be due to the occurrence of differ-
ent opportunistic infection among this group of patients,
and EFV-containing regimen had no organ damage like
hepatotoxicity and preferred for this group at large to
maintain adherence [8]. Two studies [25, 43] did not re-
port the median CD4 cell count at initiation. Only two
studies [45, 55] reported the log transformed median
viral load. NRTI backbones used differed between stud-
ies. Stavudine (d4T)/3TC were used in 13 studies, and
three studies did not use this NRTI backbone at all.
AZT/3TC was used in 14 studies, and two studies did
not use this backbone at all. TDF/3TC was used less fre-
quently, in only seven studies.
Most (11/16) of the studies used Cox proportional
hazards model for the analysis and reported adjusted
hazard ratio. Another two studies used stratified and
random effect Cox-proportional models. About seven
studies used second model (Conditional logistic regres-
sion, Poisson regression, mixed effect model and mar-
ginal structural models). Two of the studies further used
sensitivity analysis. In general, with the statistical model
used, most of the articles utilized appropriate analysis
methods (Table 1).
Treatment failure
In this review, treatment failure, the primary outcome of
interest, was measured using clinical, virological, and im-
munological criteria. Studies [10, 25, 45–47, 49–51, 54,
55] defined treatment failure as their primary outcomes.
A total of 30,069 patients were included in the ten stud-
ies. Of which, 19,584 (65%) were females. The majority,
17,950 (60%), were initiated with EFV-containing regi-
men. A total of 4842 patients experience treatment fail-
ure for both EFV and NVP drugs (2077 EFV and 2765
NVP). Study [45] defined treatment failure using two
separate (consecutive or non-consecutive) measurements
of viral load ≥ 400 copies/ml, or switch to another
NNRTI or protease inhibitor after at least one such
measurement. About 1822 (64.7%) patients were started
on EFV-containing regimen. The two groups did not dif-
fer in viral load measurement; however, patients started
on EFV had a significantly shorter time to virologic sup-
pression. Subsequently, patients started on NVP were
more likely to experience virologic failure (20.4 vs
13.8%). For study [50], the outcome was assessed at
48 weeks after initiating ART. Participant was consid-
ered as having failed at 48 week if she died prior to that
time, or had a plasma viral load ≥ 400 copies/ml (con-
firmed with repeat testing) at either the 24- or 48-week
study visits. The difference in failure rates between the
NVP-exposed and unexposed groups was 6.9%. Study
[51] was a case-control study in which case defined as
adult at least one viral load measurement > 5000 copies/
ml or meet the WHO 2006 immunological or clinical
failure criteria [56]. Controls were those on non-failing
first-line ART with a CD4 count > 400/ml within the last
12 months, at the time of case incidence. Patients who
were either pregnant or co-infected with tuberculosis at
the time of ART initiation were excluded. A total of
1084 cases were included with median time to ART fail-
ure of 37 months. Study [10] defined the outcome meas-
ure of treatment failure was a composite of death,
clinical progression or discontinuation of NNRTI for any
reason. A total of 3999 patients were involved from
whom 2369 (59%) initiated by EFV-containing ART and
633 (26.7%) experienced at least one event.
The second outcome of interest was NNRTI substitu-
tion. Studies [10, 42, 44, 48, 53] defined NNRTI skin
rash, NNRTI discontinuation, regimen change, NNRTI
substitution, and regimen change as the outcome meas-
ure, respectively. Study [25] defined immunologic re-
sponse, and study [49] patients retention as the outcome
measure. In all studies, the initial NNRTI drug was
substituted by another drug in the same regimen, hence
defined NNRTI substitution as the outcome measure.
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Studies [10, 44, 46, 47] had outcome measure of death
as an event. There were high number of death in pa-
tients who initiated with EFV, 208 (8.8%), than NVP, 110
(6.8%), containing regimen in study [10]. A total of
27,350 patients were included of whom 19,441 (71.1%)
started EFV and 7909 (28.9%) started NVP treatment. At
the end of the study period, 1593 (5.8%) patients died.
Study [47] included 12,840 patients of whom 1061 died
(8.3%) within the first 12 months on ART (Table 2).
Meta-analysis results
The overall analysis revealed presence of heterogen-
eity among the individual studies (I-squared = 97.1%)
(Fig. 2). Subgroup analysis was performed based on
the two outcomes of interest mentioned above.
The first subgroup was treatment failure with ten
studies [10, 25, 45–47, 50, 51, 54, 55, 57], and the second
subgroup was NNRTI substitution which includes stud-
ies [10, 42–44, 48, 53]. The forest plot for treatment fail-
ure subgroup revealed that studies [25, 49, 51, 54, 55]
were not statistically significant, but studies [10, 45–47]
showed significant risk of treatment failure individually.
Heterogeneity among the studies within the subgroup
was tested using I-squared statistics. The I-squared value
for treatment failure subgroup was found to be 81.0%
(p value < 0.0001) which indicated the presence of het-
erogeneity between studies. The weights of the studies
were reported from random effect model which ranged
from 0.31% to a maximum of 28.28%. The pooled estimate
of risk ratio from random effect model was 0.85 (RR = 0.85;
95%CI 0.75–0.88) for EFV than NVP for treatment failure.
For NNRTI substitution subgroup, almost all the studies
were individually significant except study [43]. The
I-squared value is 98.9% (p value = 0.0001) which indicates
as there is high heterogeneity between studies. The weight
of the studies ranges from 0.37 to 38.09%. The pooled esti-
mate from random effect model was 0.57 (RR = 0.57; 95%
CI 0.37–0.89) which is consistent with the estimate from
the fixed effect model (Fig. 3).
Evaluation for publication bias
One of the main problems in systematic review and
meta-analysis is that not all studies carried out are
published. Those which are published may be different
from those which are not. Research with statistically
significant results is more likely to be submitted and
published than work with null or non-significant results.
This could introduce bias during systematic review and
meta-analysis. The presence of publication bias was
assessed by funnel plots and tested using Egger’s test
which is proposed by Egger et al. [33] to test for asym-
metry of the funnel plot.
The funnel plot is assumed to be symmetric in the
absence of research bias. The solid vertical line represents
the summary estimate of the treatment effect. The diag-
onal lines representing the 95% confidence limit around
the summary treatment effect. These show the expected
distribution of studies in the absence of heterogeneity or
of selection biases. It seems as there are more studies
which lie to the left of the funnel plot. Egger’s test was per-
formed for each subgroup. The test revealed that there
was no significant bias for either of the outcome (overall
test: intercept = − 2.217, 95% CI − 5.562; 1.128 and p
value = 0.178) (Fig. 4).
Meta regression was performed to determine whether
there is a significant association between independent
variables in the form of study versus the dependent vari-
able. A regression model is constructed for covariates,
length of follow-up, median CD4 cell counts, median
age, and year of publication, and proportion of female.
There was no significant relationship between any of the
covariates and treatment failure which indicates that
these covariates may not be the source of observed
variability (Table 3). Bubble plot was plotted for selected
covariates (see Additional file 2).
Sensitivity analysis has been performed to identify
study which has more influence on the estimates. The
plot visually provides estimate with 95% confidence
interval, naming the omitted study on the left margin.
The lower and upper confidence interval limits were
presented for the estimates. The sensitivity analysis
revealed that there is no single study affecting the esti-
mate too much. Exclusion of [53] seems influential, but
the effect is not statistically significant (Fig. 5).
Discussion
This systematic review and meta-analysis attempted to
assess the individual and pooled estimate of the choice
of NNRTI drugs on treatment failure and NNRTI switch
in resource-poor settings. A total of 16 observational
studies were found which compares EFV versus NVP,
out of which, 17 outcome measures were identified in
two groups.
The findings revealed that initiation of ART with EFV-
containing regimen is associated with a reduced risk of
treatment failure (RR = 0.85, 95%CI 0.75–0.98) as com-
pared to NVP-containing regimen in resource-limited
settings. This finding was consistent across four of the
ten individual studies. This is in line with previous
meta-analysis [20] conducted from ten RCTs and 24 ob-
servational studies which concluded that EFV-based first
line ART regimen is significantly less likely to lead to vi-
rologic failure compared to NVP-based ART regimen.
This might be due to the hepatotoxic nature of NVP
which may lead to poor adherence which might further
resulted in treatment failure.
In the 2NN group study [58], there was no any evi-
dence that EFV is superior to NVP twice daily in terms
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Fig. 3 Relative risk of treatment failure and NNRTI substitution associated with the choice of NNRTI drugs regiment during ART initiation
Fig. 2 Relative risk of composite outcome associated with the choice of NNRTI drugs regiment during ART initiation
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of treatment failure. A Cochrane review of seven
randomized clinical trials [59] demonstrated that the two
drugs provided comparable levels of viral suppression in
patients infected with HIV when combined with two
NRTIs. In a non-randomized longitudinal cohort study
conducted in India [39], equivalent immunological
response was observed among NVP and EFV-based ART.
The risk ratio of NNRTI switch reduced by 0.57 (95%
CI 0.37–0.89) times for patients who initiated with EFV
than NVP. This finding is consistent with a multicenter
randomized non-inferiority trial [60] in which the
switching rate is higher among patients who initiated
with NVP than EFV. This finding is also consistent with
previous meta-analyses [21] which revealed that adults
on NVP were two times more likely to discontinue treat-
ment due to any adverse event compared to patients on
EFV. Another meta-analysis on five randomized clinical
trials and four retrospective clinical trials [61] revealed
that the discontinuation rate was high among those who
initiated with NVP than EFV which is consistent with
this review. Similar finding was reported by meta-
analysis of 26 RCTs [62] in which the discontinuation
rate was lower among those who initiated with EFV than
NVP-containing regimen.
The source of heterogeneity was assessed using meta-
regression. Covariates length of follow-up, median CD4
cell counts, median age, and year of publication were in-
cluded in the regression model. The log relative risk of
treatment failure was not a significant difference among
length of follow-up, median CD4 cell counts, median
age, or year of publication. This might be due to the
small number of included studies in the analysis. Sensi-
tivity analysis also revealed that there is no single study
which influences the pooled estimate.
These results need to be interpreted with caution due
to limitations. Although a lot of efforts have been made
to find more studies, still there were few studies which
satisfied the inclusion criteria. The analysis was limited
to only articles published in English language; the
evidence may not be sufficiently robust to determine the
comparative effectiveness of EFV and NVP due to the
size of included studies. In addition, the analysis
included articles with different definitions of treatment
failure and different lengths of follow-up. The reviewed
articles have also differences in study design, the type of
statistical methods, and the variables included in the
analysis. These variations may have resulted in selection
bias or low statistical power, thus hindering results. Most
of our analyses detected heterogeneity between effect
estimates obtained across studies. DerSimonian and
Laird random effect model was used to determine the
pooled effect size [32, 33]. However, the source of
variation might not be real heterogeneity rather within
study differences which may introduce bias on the
pooled effect size.
Fig. 4 Funnel plot of effect estimates against standard error of log estimate
Table 3 Parameter estimates of meta-regression
Covariate Estimate S.E 95%CI
Length of follow-up − 0.0138 0.0666 (− 0.1322–0.1046)
Median CD4 count − 0.0034 0.0066 (− 0.0150–0.0079)
Median age 0.0415 0.0503 (− 0.1013–0.0755)
Year of publication 0.0637 0.0815 (− 0.1736–0.0980)
Female proportion − 0.5305 1.4575 (− 3.6792–2.6183)
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Conclusion
The finding of this review showed that initiation of ART
with EFV-containing regimen has reduced risk of
treatment failure as compared to NVP-containing
regimen. In addition, the patients who initiated with
EFV are less likely to switch than those with NVP. In
contrast, there was about 50% increased risk of death in
patients who initiated with EFV as compared to NVP-
containing regimens. Even though EFV is more expen-
sive to afford for resource-poor settings, initiating the
patient with EFV-containing regimen could be supreme
important.
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